Arrowhead Pharmaceuticals, Inc.

Novartis Ag

Arrowhead Research Corporation

Wenlai Zhou

Ping Zhu

Gregory Hinkle

Stuart Milstein

Satyanarayana Kuchimanchi

Tracy Stage Zimmermann

Markus Warmuth

Jinyun Chen

Chandra Vargeese

Jan Weiler

Giordano Caponigro

Dieter Huesken

Vesselina Cooke

Frank Peter Stegmeier

Manav Korpal

Scott Delach

Kalyani Gampa

Mark Stump

Joshua Korn

Jan Wieler

The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

Organic compositions to treat HSF1-related diseases

The present disclosure relates to methods of treating heat stock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 877 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 742 and 878 is also shown to be useful for patient stratification.

Androgen receptor mutation

Growing community of inventors

Cambridge, MA, United States of America

Wenlai Zhou